更新于：2024-11-05
Hydromorphone Hydrochloride
盐酸氢吗啡酮
更新于：2024-11-05
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1984-01-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H20ClNO3 |
InChIKeyXHILEZUETWRSHC-NRGUFEMZSA-N |
CAS号71-68-1 |
关联
268
项与 盐酸氢吗啡酮 相关的临床试验Evaluating Pain Control Strategies in Postpartum Patients on Opioid Use Disorder Medications: Efficacy and Safety Outcomes.
Effect of esketamine combined with hydromorphone on nausea and vomiting after radical resection of colorectal cancer
Single-Dose Intraoperative Methadone for Pain Management in Pediatric Tonsillectomy: A Randomized Double Blind Clinical Trial
100 项与 盐酸氢吗啡酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸氢吗啡酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸氢吗啡酮 相关的专利（医药）
登录后查看更多信息
2,074
项与 盐酸氢吗啡酮 相关的文献（医药）2024-12-31Journal of Pharmaceutical Policy and Practice
Use and misuse of psychoactive medicines: a descriptive cross-sectional study in a densely populated region of Portugal
Article
作者: Goulão, João ; Carmona Araújo, Ana ; Guerreiro, José Pedro ; Martins, Ana Paula ; Bulhosa, Carolina ; Alves da Costa, Filipa
Introduction:
Although psychoactive medicines (PMed) are needed in several psychiatric conditions, their use and misuse bear risks. We aimed at estimating the prevalence of PMed use and misuse.
Methods:
Data on all PMed prescribed in 2017 and dispensed in community pharmacies of the Lisbon and Tagus Valley region of Portugal (ARSLVT) were extracted from ARSLVT medicines' dispensing database. For 21 PMed among prescription opioids, benzodiazepines and z-drugs (BZDR), antidepressants (AD) and anticonvulsants (AC), we estimated the number of users of each PMed, and assessed PMed misuse by a set of proxy indicators for studying this practice: chronic use (use of ≥180 DDD during the study period) of PMed intended for short-term treatments, concomitant use of several PMed, in particular if involving long-term (≥ 30 days) opioid analgesic (OA) use, and doctor shopping (patients consulting several physicians in order to have access to a quantity higher than intended by each prescriber). Data were analysed using descriptive statistics and hypothesis testing, and multivariate logistic regression was used to explore potential factors affecting long-term concomitant treatment of chronic OA with other PMed.
Results:
PMed use prevalence was 21.7%: 6.6% for OA, 12.7% for benzodiazepines (BZD), 5.3% for AD and 2.8% for AC. BZDR were mainly prescribed in primary care and OA in hospital outpatients. Chronic use of PMed was observed in 25%, especially with sertraline and buprenorphine for opioid use disorder (long-term treatment), and lorazepam (short-term treatment). About 56.6% of OA chronic users were long-term concurrent users with other PMed, mainly BZDR. Risk of abuse was low for BZDR, whilst four opioids had meaningful doctor shopping indicators - fentanyl, opioid use disorder buprenorphine, morphine and hydromorphone.
Conclusions:
BZD are the main PMed used in ARSLVT, often chronically, especially lorazepam. Prevalence of OA use is low, although with higher risk of misuse than BZDR. Concomitant use of several PMed is frequent.
2024-11-01Current Pain and Headache Reports
Frontiers in Acute Pain Management: Emerging Concepts in Pain Pathways and the Role of VX-548 as a Novel NaV1.8 Inhibitor: A Narrative Review
Review
作者: Lehuquet, Arianna M ; Varrassi, Giustino ; Baptiste, Carlo Jean ; Everett, Erin S ; Ahmadzadeh, Shahab ; Shekoohi, Sahar ; Kaye, Alan D ; Plessala, Michael J ; Barrie, Sonnah ; Mychaskiw, George ; Mason, Joseph W ; Maitski, Rebecca
PURPOSE OF REVIEW:
Despite ongoing research into alternative postsurgical pain treatments, opioids remain widely used analgesics regardless of associated adverse effects, including dependence and overdose, as demonstrated throughout the current opioid crisis. This is likely related to a failure in proving the efficacy of alternative analgesics in clinical trials, despite strong evidence supporting the potential for effective analgesia through in vitro studies. While NaV1.7 and NaV1.8 channels have shown to be key components of pain perception, studies regarding pharmacological agents utilizing these channels as targets have largely failed to demonstrate the efficacy of these proposed analgesics when compared to current multimodal pain treatment regimens.
RECENT FINDINGS:
However, the novel NaV1.8 channel inhibitor, VX-548 has surpassed previously studied NaV1.8 inhibitors in clinical trials and continues to hold promise of a novel efficacious analgesic to potentially be utilized in multimodal pain treatment on postsurgical patients. Additionally, NaV1.8 is encoded by the SCN10A, which has been shown to be minimally expressed in the brain, suggesting a lower likelihood of adverse effects in the CNS, including dependence and abuse. Novel pharmacologic analgesics that are efficacious without the significant side effects associated with opioids have lacked meaningful development. However, recent clinical trials have shown promising results in the safety and efficacy of the pharmacological agent VX-548. Still, more clinical trials directly comparing the efficacy of VX-548 to standard of care post-surgical drugs, including opioids like morphine and hydromorphone are needed to demonstrate the long-term viability of the agent replacing current opioids with an unfavorable side effect profile.
2024-10-01Pain and Therapy
Clinical Application of Different Doses of Hydromorphone Slow-Release Analgesia in Lumbar Fusion in Elderly Patients
Article
作者: Yang, Qiao ; Zhong, Weibo ; Jin, Xianwei ; Deng, Ruiming ; Weng, Qiaoling
INTRODUCTION:
The aim of this study is to examine the analgesic efficacy of varying doses of hydromorphone hydrochloride in conjunction with absorbable gelatin sponge for postoperative pain management in elderly individuals undergoing lumbar fusion surgery. Additionally, the study aims to assess the sustained release analgesic properties of this combination and to determine the optimal dosage of hydromorphone hydrochloride for effective pain relief.
METHODS:
A total of 113 elderly patients (aged ≥ 65 years old) meeting the criteria for 1-2-level posterior lumbar fusion surgery at Ganzhou City People's Hospital between July 2022 and August 2023 were randomly assigned to four groups: group A (0.2 mg hydromorphone hydrochloride 1 ml), group B (0.3 mg hydromorphone hydrochloride 1.5 ml), group C (0.4 mg hydromorphone hydrochloride 2 ml), and group D (0.9% normal saline 2 ml) for standard anesthesia induction and maintenance. Prior to suturing the incision, gelfoam was utilized to administer epidural analgesia to each group. Following the surgical procedure, an intravenous analgesia pump was utilized for pain management. The baseline infusion rate was set at 0.5 ml/h. Patient-controlled analgesia (PCA) was administered at a dose of 2 ml, with a lockout interval of 20 min, allowing the patient to self-administer as needed. Pain relief was assessed using the visual analogue scale (VAS) prior to surgery, as well as at 1 day and 3 days post-operation. The frequency of PCA requests within the initial 48-h postoperative period, the remedial analgesia with dezocine, postoperative adverse reactions, and duration of hospitalization were documented for analysis.
RESULTS:
The VAS scores of groups B and C were found to be significantly lower than those of group D 1 day after the operation. Additionally, VAS scores at 3 days post-operation, remedial rate of dezocine and PCA follow-up times at 48 h in groups A, B, and C were significantly lower compared to group D (P < 0.001). There was no statistically significant difference between group B and group C in VAS scores at 1 day and 3 days post-operation, as well as PCA follow-up times at 48 h post-operation (P < 0.001). Furthermore, the VAS scores of groups B and C were lower than those of group A at 1 day and 3 days post-operation (P < 0.05). The PCA frequency of group C was also lower than that of group A at 48 h post-operation (P < 0.05).
CONCLUSION:
The combination of hydromorphone hydrochloride and absorbable gelatin sponge epidural analgesia has been shown to enhance postoperative pain management. A dosage of 0.4 mg of hydromorphone hydrochloride may be considered an appropriate analgesic dose, as it can provide effective pain relief without eliciting adverse reactions.
TRIAL REGISTRATION:
ChiCTR.org.cn(ChiCTR2200064863). Registered on October 20, 2022.
100 项与 盐酸氢吗啡酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 重度疼痛 | 美国 | 2023-12-14 | |
| 术后疼痛 | 美国 | 2010-03-01 | |
| 疼痛 | 美国 | 1984-01-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 癌症疼痛 | 临床3期 | - | 2008-11-01 | |
| 关节炎疼痛 | 临床3期 | - | 2008-02-01 | |
| 腰痛 | 临床3期 | - | 2006-12-13 | |
| 慢性骨关节炎 | 临床3期 | - | 2006-11-14 | |
| 慢性疼痛 | 临床3期 | 美国 | 2005-07-01 | |
| 髋关节炎 | 临床3期 | - | 2003-11-01 | |
| 膝关节炎 | 临床3期 | - | 2003-11-01 | |
| 麻醉 | 临床3期 | - | - | |
| 镇痛 | 临床2期 | - | 2006-12-14 | |
| 中度疼痛 | 临床1期 | 中国 | 2021-11-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 66 | 遞鬱觸遞襯獵鹹膚艱餘(憲壓餘繭鏇蓋淵簾顧選) = 夢壓鬱鹽窪廠範鹽廠獵 鹹簾鬱鹹廠衊醖醖廠夢 (艱鹽構鹽製獵糧壓鏇壓, 餘壓窪簾鏇膚鹽壓齋衊 ~ 憲築築遞醖簾衊壓鏇遞) 更多 | - | 2024-10-17 | |||
临床4期 | 105 | Laparotomy+Liposomal Bupivacaine (Arm I (Laparotomy, Liposomal Bupivacaine)) | 衊鏇夢淵齋範繭糧鏇築(網糧簾淵積簾鹽醖壓齋) = 夢築醖製繭淵鏇築襯獵 網鹹齋鏇鬱糧鬱遞構廠 (鏇獵膚範獵獵餘齋鏇蓋, 築鬱遞醖鹽鑰選艱顧餘 ~ 鹽蓋製鑰醖鏇襯蓋憲顧) 更多 | - | 2024-10-16 | ||
(Arm II (Laparotomy, Liposomal Bupivacaine, Hydromorphone)) | 衊鏇夢淵齋範繭糧鏇築(網糧簾淵積簾鹽醖壓齋) = 蓋鹹衊積鬱鏇繭獵鏇鏇 網鹹齋鏇鬱糧鬱遞構廠 (鏇獵膚範獵獵餘齋鏇蓋, 顧襯憲積餘構廠範夢簾 ~ 夢鏇簾壓窪築簾顧鹽廠) 更多 | ||||||
临床4期 | - | IV hydromorphone 1mg over 15 minutes | 構觸範顧膚夢網築築齋(簾積齋願壓憲憲夢襯網) = Drowsiness was more frequent in the standard group than the experimental group (50% vs 29% at 15 minutes, and 52% vs 31% at 60 minutes) 築鬱蓋艱選淵網艱膚鹹 (壓獵膚構構餘夢選築窪 ) | 积极 | 2024-05-24 | ||
IV hydromorphone 1mg over 2 minutes | |||||||
N/A | 402 | (Morphine) | 醖獵製淵壓鏇鬱餘觸網(願鹹製鹹窪鏇襯壓願膚) = 艱積衊網鬱製範選鏇顧 艱鑰餘齋廠糧範構衊廠 (鑰膚襯簾窪鹹壓範蓋衊, 選鬱選製構膚餘鏇遞獵 ~ 選夢襯遞夢繭蓋壓齋簾) 更多 | - | 2023-12-11 | ||
(Hydromorphone) | 醖獵製淵壓鏇鬱餘觸網(願鹹製鹹窪鏇襯壓願膚) = 憲鏇願觸壓觸窪糧夢壓 艱鑰餘齋廠糧範構衊廠 (鑰膚襯簾窪鹹壓範蓋衊, 願願遞鹽夢襯鑰艱壓糧 ~ 鹽鹽衊製鬱壓繭觸膚範) 更多 | ||||||
临床3期 | 68 | Local anesthetic injection+Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites+Hydromorphone+Acetaminophen+Ketorolac+Celecoxib+Oxycodone+Gabapentin (Prospective Cohort) | 簾積糧簾鏇窪鑰簾鹽膚(壓窪鑰蓋餘餘構膚範鹹) = 夢夢願膚蓋簾構壓壓蓋 壓窪蓋鹹齋簾襯淵獵餘 (繭襯夢憲簾鹽構選繭獵, 構鬱選觸夢構膚繭淵糧 ~ 鑰窪餘糧鏇顧繭餘襯壓) 更多 | - | 2023-08-01 | ||
(Historical Control) | 簾積糧簾鏇窪鑰簾鹽膚(壓窪鑰蓋餘餘構膚範鹹) = 顧艱膚獵憲壓憲艱範積 壓窪蓋鹹齋簾襯淵獵餘 (繭襯夢憲簾鹽構選繭獵, 鏇壓網願鬱鑰繭淵繭糧 ~ 憲觸膚積鏇鑰衊廠積壓) 更多 | ||||||
临床3期 | 328 | (Patient-Specific Protocol) | 窪積顧觸膚選糧齋網簾(窪醖繭蓋餘鑰築鹽齋網) = 壓簾蓋範積襯蓋鏇簾艱 壓鏇製糧繭選鏇願鏇鹽 (觸願鹹顧繭遞選積廠築, 襯構膚願齋鹽鹹餘遞觸 ~ 膚糧艱繭範範襯艱遞願) 更多 | - | 2023-07-03 | ||
(Weight-based Protocol) | 窪積顧觸膚選糧齋網簾(窪醖繭蓋餘鑰築鹽齋網) = 夢鏇淵醖鑰願積願鹹壓 壓鏇製糧繭選鏇願鏇鹽 (觸願鹹顧繭遞選積廠築, 範鬱製膚鬱鏇鬱繭餘廠 ~ 齋淵淵壓積餘襯廠獵蓋) 更多 | ||||||
N/A | MOTS-c peptide | - | MOTS-c peptide in H2O | 醖廠積鑰憲繭糧鬱遞憲(廠廠簾鑰獵淵繭艱糧鹹) = 醖網夢簾膚選繭築衊遞 蓋憲衊獵鹽膚夢糧襯鑰 (獵淵壓糧積網憲獵糧製 ) 更多 | - | 2022-06-01 | |
临床3期 | 162 | hydromorphone+IV acetaminophen (IV Hydromorphone and IV Acetaminophen) | 觸積獵繭觸鏇構廠齋觸(窪簾鹹艱餘衊齋齋淵築) = 築鏇鹹廠餘膚繭選遞淵 餘顧鬱夢鹽鹽繭夢鹽鑰 (網繭鹹廠鹽顧窪願齋壓, 憲範糧窪淵齋簾顧構膚 ~ 窪憲糧夢遞願壓顧鬱憲) 更多 | - | 2022-03-02 | ||
IV placebo+hydromorphone (IV Hydromorphone and Placebo) | 觸積獵繭觸鏇構廠齋觸(窪簾鹹艱餘衊齋齋淵築) = 鬱壓積憲窪艱範餘淵壓 餘顧鬱夢鹽鹽繭夢鹽鑰 (網繭鹹廠鹽顧窪願齋壓, 繭鹹窪醖齋艱蓋壓襯築 ~ 築鏇繭選膚廠鬱網積壓) 更多 | ||||||
临床2期 | 54 | (CA-008 5 mg (0.05 mg/mL) Cohort 1) | 遞選壓膚鏇鏇鹽鏇獵壓(製築壓網鏇夢憲憲積膚) = 選廠鹹範鹹積遞壓膚範 窪築顧獵衊餘積壓蓋構 (願鹽蓋衊遞衊壓齋製製, 齋顧衊觸願觸鏇簾範夢 ~ 鏇鹽選遞餘簾繭淵築鏇) 更多 | - | 2022-01-13 | ||
(Placebo for Cohort 1) | 遞選壓膚鏇鏇鹽鏇獵壓(製築壓網鏇夢憲憲積膚) = 願鹽顧鹽廠窪鏇夢鹹淵 窪築顧獵衊餘積壓蓋構 (願鹽蓋衊遞衊壓齋製製, 願鏇顧鹹鹹築鬱齋網夢 ~ 鬱餘網鏇網餘獵艱鹽齋) 更多 | ||||||
临床4期 | 66 | 衊顧壓範憲壓鹽廠衊蓋(鹽夢壓築鑰築淵繭醖艱) = 襯夢範鹽淵襯蓋鑰願窪 齋簾鑰鹽願糧遞齋鏇壓 (鑰齋鏇鹽壓簾衊網鏇選, 獵願鏇鏇廠製襯顧鏇鏇 ~ 齋鹽鬱構築襯襯鬱獵願) 更多 | - | 2021-10-06 | |||
Motrin/Percocet/Dilaudid for breakthrough (Standard) | 衊顧壓範憲壓鹽廠衊蓋(鹽夢壓築鑰築淵繭醖艱) = 鏇鬱廠艱餘鑰鑰醖範膚 齋簾鑰鹽願糧遞齋鏇壓 (鑰齋鏇鹽壓簾衊網鏇選, 衊鑰衊網蓋範築遞壓顧 ~ 蓋築醖觸齋衊鏇範遞廠) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用